학술논문
Multicenter retrospective study of nivolumab for recurrent/metastatic oral squamous cell carcinoma.
Document Type
Article
Author
Yamakawa, Nobuhiro; Umeda, Masahiro; Yoshii, Yumi; Mitsudo, Kenji; Noguchi, Makoto; Kusukawa, Jingo; Katakura, Akira; Nakayama, Hideki; Sasaki, Masashi; Noguchi, Tadahide; Ueda, Michihiro; Bukawa, Hiroki; Yagihara, Kazuhiro; Horie, Akihisa; Miyazaki, Akihiro; Chikazu, Daichi; Tomihara, Kei; Mishima, Katsuaki; Otsuru, Mitsunobu; Asoda, Seiji
Source
Subject
*DRUG efficacy
*RESEARCH
*MOUTH tumors
*SCIENTIFIC observation
*MULTIVARIATE analysis
*CANCER relapse
*METASTASIS
*RETROSPECTIVE studies
*NIVOLUMAB
*DESCRIPTIVE statistics
*PROGRESSION-free survival
*SQUAMOUS cell carcinoma
*PATIENT safety
*OVERALL survival
*EVALUATION
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1354-523X
Abstract
Objectives: Immunotherapy with nivolumab for patients with recurrent/metastatic oral squamous cell carcinoma has not been evaluated. Here, we aimed to examine the efficacy, safety, and prognostic factors of nivolumab in these patients. Materials and Methods: This multicenter retrospective observational study involved patients who received nivolumab between April 2017 and June 2019. The patient characteristics were evaluated for association with progression‐free and overall survival. Progression‐free and overall survival rates were calculated; parameters that were significant in the univariate analysis were used as explanatory variables. Independent factors for progression‐free and overall survival were identified using multivariate analysis. Results: Totally, 143 patients were included. The overall response and disease control rates were 27.3% and 46.2%, respectively. The median, 1‐ and 2‐year progression‐free survival rates were 2.7 months, 25.4%, and 19.2%, respectively; those for overall survival were 11.2 months, 47.3%, and 33.6%, respectively. The independent factors affecting progression‐free survival were performance status and immune‐related adverse event occurrence, whereas those affecting overall survival were performance status, target disease, and number of previous lines of systemic cancer therapy. Eight patients reported grade ≥3 immune‐related adverse events. Conclusion: Nivolumab was effective for recurrent/metastatic oral squamous cell carcinoma treatment and was well tolerated by patients. [ABSTRACT FROM AUTHOR]